BRISBANE, Calif. — November 5, 2025 — Leads & Copy — Vera Therapeutics, Inc. (Nasdaq: VERA) reported its business highlights and financial results for the third quarter ended September 30, 2025. The ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) were selected as a featured late-breaking oral presentation during the opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025. A Biologics License Application (BLA) submission through the Accelerated Approval Program for atacicept for the treatment of IgAN to U.S. FDA is expected in Q4, and a potential U.S. commercial launch of atacicept in 2026. Patients are being actively enrolled in the PIONEER, atacicept monthly dose range finding, and ORIGIN Extend studies.
Vera Therapeutics, a late clinical-stage biotechnology company, reported a net loss of $80.3 million for the quarter ended September 30, 2025, compared to a net loss of $46.6 million for the same period in 2024. As of September 30, 2025, Vera Therapeutics reported $497.4 million in cash, cash equivalents, and marketable securities, which the company believes is sufficient to fund operations through potential approval and U.S. commercial launch of atacicept and beyond.
Vera Therapeutics’ CEO, Marshall Fordyce, M.D., said the company is excited to share additional data and clinical experience regarding the treatment of IgAN during ASN Kidney Week later this week. Dr. Fordyce also stated the company remains on track to submit the BLA for atacicept in IgAN to the FDA this quarter.
Contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
Source: Vera Therapeutics, Inc.
